Press Releases Items Per Page 102550 Year None2020201920182017201620152014 04-01-2020 Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene® 03-30-2020 Daré Bioscience Reports 2019 Financial Results and Provides a Company Update 03-24-2020 Daré Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020 03-10-2020 Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis 03-09-2020 Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder 02-27-2020 Daré Bioscience to Present at the Cowen 40th Annual Health Care Conference 02-06-2020 Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates 02-05-2020 Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference 01-30-2020 Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule 01-15-2020 Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 11
04-01-2020 Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene®
03-24-2020 Daré Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020
03-10-2020 Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis
03-09-2020 Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder
02-06-2020 Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
01-15-2020 Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update
